It develops when there is excess fat in liver cells due to too much fatty acid uptake in the liver, excess synthesis of fat in the liver, and not enough fat exported out of the liver
GLP-1 therapy is, in most cases, chronic
This means that Mounjaro differs mechanistically from Wegovy
Food and Drug Administration (FDA) to treat Type 2 diabetes
Meta-analyses using data from randomized, controlled CV outcomes trials showed that GLP-1 RAs were associated with a significant reduction in the risk of three-component major adverse CV events (CV death, non-fatal myocardial infarction and non-fatal stroke), and a significant reduction in the risk of fatal or non-fatal stroke, versus placebo in addition to standard-of-care (SoC) treatment [13, 14]
She is actively involved in Missionary and Philanthropy work as well